following a full submission:
dostarlimab (Jemperli®) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment.
Indication under review: as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
In a single-arm cohort of a phase I study in patients with dMMR/MSI-H recurrent or advanced endometrial cancer who had progressed following treatment with platinum doublet chemotherapy, dostarlimab was associated with an objective response rate (ORR) of 44%, median duration of response has not been reached.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- dostarlimab (Jemperli)
- SMC ID:
- SMC2404
- Indication:
Monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum‑containing regimen.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Interim acceptance
- Date advice published
- 07 March 2022